surmount-1 trial tirzepatide non-diabetic weight loss (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants Tirzepatide lowers body weight for

For patients paying out of pocket for weight loss treatment, Zepbound vials are significantly more affordable than Mounjaro at retail pricing, making Zepbound the better choice for cash-paying patients seeking tirzepatide

Patients exploring international options should be aware of tirzepatide availability in Mexico and grey market tirzepatide considerations , though domestic compounded sources typically offer better safety assurances

It is a sign that the peptide is active and the body is adjusting

People maintaining treatment continue experiencing appetite suppression and weight loss maintenance as long as they continue the medication

ClinicalTrials.gov identifier: NCT06445075